Data Show Barriers to Immunotherapy Access in Clear Cell RCC Population
Findings from a retrospective analysis indicate that treatment in non-academic cancer centers correlates with a decreased rate of immunotherapy use among patients with advanced clear cell renal cell carcinoma.
MAGNITUDE Trial Highlights OS Benefit with Niraparib Combo in BRCA+ mCRPC
Data from the MAGNITUDE trial support the positive benefit/risk profile of niraparib plus abiraterone acetate and prednisone as a treatment for those with BRCA-mutated metastatic castration-resistant prostate cancer.
Radioligand/Enzalutamide Improves PSA-PFS in Metastatic CRPC
Findings from the ENZA-p study provide evidence for enhanced anti-cancer effects with 177Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
No Improvement in OS With Extended Vs Standard Lymphadenectomy in MIBC
Findings from the phase 3 SWOG S1011 trial highlight no significant differences between extended lymphadenectomy vs standard lymphadenectomy in terms of disease-free survival in patients with muscle-invasive breast cancer.
Talazoparib/Enzalutamide Combo Appears Tolerable in Prostate Cancer
A recent phase 3 trial of the combination included a total of 398 patients with metastatic castration-resistant prostate cancer, unselected for homologous recombination repair gene alterations, in the safety cohort.
Adding Blue Light Cystoscopy to Standard White Light Decreases Tumor Recurrence in a Type of Bladder Cancer
Findings from an interim analysis of data show that the addition of blue light cystoscopy to conventional white light significantly improved clinical outcomes in a group of patients with non–muscle-invasive bladder cancer.
2 Clarke Drive Cranbury, NJ 08512